The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The IMPACT of an interdisciplinary goals-of-care program on readmission rates at a comprehensive care center.
 
Cerena Leung
No Relationships to Disclose
 
Clark R. Andersen
No Relationships to Disclose
 
Kaycee Wilson
No Relationships to Disclose
 
Nico Nortje
No Relationships to Disclose
 
Marina C. George
Honoraria - UpToDate (I)
Consulting or Advisory Role - Daiichi Sankyo (I); Marvin Health (I)
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; Karyopharm Therapeutics; MorphoSys; Pharmacyclics/Janssen; SeaGen; Spectrum Pharmaceuticals
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
Eduardo Bruera
Research Funding - PharmaCann (Inst)
 
David Hui
Consulting or Advisory Role - Eton Pharmaceuticals